Industry-Validated, Proprietary Platform

More than two dozen partners have leveraged Atlas Mice to generate high‑quality human antibodies across 75+ discovery programs. This work has now translated into clinical impact, with the first Atlas Mouse‑derived therapeutic entering Phase 1 development in Q1 2026.

Fit-for-Partner Business Model

We build durable collaborations rooted in a deep understanding of our partners’ goals to create long-term value for both parties. Our flexible business terms—from milestone- and royalty-free structures to pay-upon-success models—are designed to meet you where you are today and scale with you as your needs evolve.

Flexible Platform Access

Breakthrough science demands more than a technology fit. We structure each partnership to align with your scientific priorities, operational model, and business goals.

• Platform licensing: Deploy our next‑generation antibody discovery technologies at your site or through a designated service provider.
• Co‑discovery: Combine our complementary expertise and differentiated platforms to unlock therapeutics for multispecifics, GPCRs, and other challenging targets.

Proven Expertise

Our team has been at the forefront of developing and deploying many of the industry’s most impactful transgenic human antibody discovery platforms, including those at Medarex, Ablexis / AlivaMab Biologics, and Alloy Therapeutics. This collective expertise has powered more than 2,000 successful antibody discovery campaigns and contributed to at least 13 marketed therapeutics.

Contact us to explore how AbTherx can power your next antibody discovery program.